AYVAKIT ™ (avapritinib), FDA Approved for Treatment of PDGFRA Exon 18 Mutant GIST, Available at Biologics by McKesson

CARY, N.C., Jan. 17, 2020 —Biologics by McKesson, an independent specialty pharmacy for oncology and other rare and complex therapeutic areas, has been selected by Blueprint Medicines Corporation as a specialty pharmacy provider for AYVAKITTM (avapritinib) for the treatment of adults with unresectabl...
Source: McKesson News - Category: Information Technology Source Type: news